EGR1 and hepatocellular carcinoma: Bi et al. believe that miR-181a-5p is a negative regulator of Egr1 and can inhibit tumor proliferation in HCC by targeting the Egr1/TGF-β1/Smad pathway, which may be a potential therapeutic approach for HCC [49].